HRP20110622T1 - Upotreba inhibitora c1 u sprječavanju ishemijsko-reperfuzijske ozljede - Google Patents
Upotreba inhibitora c1 u sprječavanju ishemijsko-reperfuzijske ozljede Download PDFInfo
- Publication number
- HRP20110622T1 HRP20110622T1 HR20110622T HRP20110622T HRP20110622T1 HR P20110622 T1 HRP20110622 T1 HR P20110622T1 HR 20110622 T HR20110622 T HR 20110622T HR P20110622 T HRP20110622 T HR P20110622T HR P20110622 T1 HRP20110622 T1 HR P20110622T1
- Authority
- HR
- Croatia
- Prior art keywords
- use according
- inhibitor
- ischemia
- reperfusion injury
- intended
- Prior art date
Links
- 206010063837 Reperfusion injury Diseases 0.000 title claims abstract 7
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 208000012947 ischemia reperfusion injury Diseases 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 208000028867 ischemia Diseases 0.000 claims abstract 8
- 230000010410 reperfusion Effects 0.000 claims abstract 4
- 102000055157 Complement C1 Inhibitor Human genes 0.000 claims 6
- 108700040183 Complement C1 Inhibitor Proteins 0.000 claims 6
- 241001465754 Metazoa Species 0.000 claims 5
- 230000009261 transgenic effect Effects 0.000 claims 4
- WPAHVUADNLXSOM-SNVBAGLBSA-N 3-[5-chloro-6-[(1R)-1-pyridin-2-ylethoxy]-1,2-benzoxazol-3-yl]propanoic acid Chemical compound ClC=1C(=CC2=C(C(=NO2)CCC(=O)O)C=1)O[C@H](C)C1=NC=CC=C1 WPAHVUADNLXSOM-SNVBAGLBSA-N 0.000 claims 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- 230000001154 acute effect Effects 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 239000003527 fibrinolytic agent Substances 0.000 claims 2
- 125000005629 sialic acid group Chemical group 0.000 claims 2
- 229960000103 thrombolytic agent Drugs 0.000 claims 2
- 241000283690 Bos taurus Species 0.000 claims 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 claims 1
- 101001081555 Homo sapiens Plasma protease C1 inhibitor Proteins 0.000 claims 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims 1
- 241000283953 Lagomorpha Species 0.000 claims 1
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 claims 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 claims 1
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 claims 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 claims 1
- 241000283973 Oryctolagus cuniculus Species 0.000 claims 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229930182830 galactose Natural products 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 102000044507 human SERPING1 Human genes 0.000 claims 1
- 239000008267 milk Substances 0.000 claims 1
- 210000004080 milk Anatomy 0.000 claims 1
- 235000013336 milk Nutrition 0.000 claims 1
- 229950006780 n-acetylglucosamine Drugs 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 230000009984 peri-natal effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 abstract 2
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Surgery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05112630 | 2005-12-21 | ||
| US76094406P | 2006-01-23 | 2006-01-23 | |
| PCT/NL2006/050321 WO2007073186A2 (en) | 2005-12-21 | 2006-12-19 | Use of c1 inhibitor for the prevention of ischemia-reperfusion injury |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20110622T1 true HRP20110622T1 (hr) | 2011-09-30 |
Family
ID=38016640
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110622T HRP20110622T1 (hr) | 2005-12-21 | 2011-08-25 | Upotreba inhibitora c1 u sprječavanju ishemijsko-reperfuzijske ozljede |
| HRP20171738TT HRP20171738T1 (hr) | 2005-12-21 | 2017-11-13 | Upotreba inhibitora c1 u sprječavanju ishemijsko-reperfuzijske ozljede |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20171738TT HRP20171738T1 (hr) | 2005-12-21 | 2017-11-13 | Upotreba inhibitora c1 u sprječavanju ishemijsko-reperfuzijske ozljede |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US8071532B2 (ko) |
| EP (2) | EP1965831B1 (ko) |
| JP (2) | JP5394748B2 (ko) |
| KR (1) | KR101508668B1 (ko) |
| AT (1) | ATE516043T1 (ko) |
| AU (1) | AU2006327989B2 (ko) |
| CA (1) | CA2632400C (ko) |
| CY (2) | CY1112452T1 (ko) |
| DK (1) | DK2380587T3 (ko) |
| HR (2) | HRP20110622T1 (ko) |
| IL (2) | IL192180A (ko) |
| NZ (1) | NZ568749A (ko) |
| PL (2) | PL1965831T3 (ko) |
| SI (1) | SI2380587T1 (ko) |
| WO (1) | WO2007073186A2 (ko) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1551987A1 (en) * | 2002-10-17 | 2005-07-13 | Pharming Intellectual Property B.V. | Protein modification |
| US8071532B2 (en) | 2005-12-21 | 2011-12-06 | Pharming Intellectual Property B.V. | Use of C1 inhibitor for the prevention of ischemia-reperfusion injury |
| CA3154415A1 (en) * | 2006-10-10 | 2008-04-17 | Regenesance B.V. | Anti-sense oligonucleotide for use in facilitating axonal regeneration |
| JP5423266B2 (ja) * | 2009-09-14 | 2014-02-19 | 富士電機株式会社 | デジタル制御スイッチング電源装置 |
| EP2497489A1 (en) * | 2011-03-09 | 2012-09-12 | CSL Behring GmbH | Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs |
| WO2012120128A1 (en) * | 2011-03-09 | 2012-09-13 | Csl Behring Gmbh | Factor xii inhibitors for the administration with medical procedures comprising contact with artificial surfaces |
| DK2758076T3 (en) | 2011-09-24 | 2019-04-01 | Csl Behring Gmbh | COMBINATION THERAPY USING IMMUNOGLOBULIN AND C1 INHIBITOR |
| US10531655B2 (en) | 2011-12-02 | 2020-01-14 | The Regents Of The University Of California | Reperfusion protection solution and uses thereof |
| WO2013093027A1 (en) | 2011-12-22 | 2013-06-27 | Csl Behring Gmbh | Use of c1-inhibitor for the treatment of secondary edema of the central nervous system |
| WO2014008242A1 (en) * | 2012-07-03 | 2014-01-09 | The Trustees Of Columbia University In The City Of New York | The use of interleukin-11 to protect against ischemia and reperfusion injury |
| CN110818798A (zh) | 2012-10-25 | 2020-02-21 | 美国比奥维拉迪维股份有限公司 | 抗补体C1s抗体和其用途 |
| AU2013337638B2 (en) | 2012-11-02 | 2018-10-25 | Bioverativ Usa Inc. | Anti-complement C1s antibodies and uses thereof |
| US10441631B2 (en) | 2013-02-28 | 2019-10-15 | Csl Behring Gmbh | Therapeutic agent for amniotic fluid embolism |
| AU2014224599B2 (en) * | 2013-03-08 | 2018-11-08 | Csl Behring Gmbh | Treatment and prevention of remote ischemia-reperfusion injury |
| NZ710730A (en) | 2013-03-15 | 2021-07-30 | Viropharma Biologics Llc | C1-inh compositions and methods for the prevention and treatment of disorders associated with c1 esterase inhibitor deficiency |
| JP2017501968A (ja) * | 2013-06-28 | 2017-01-19 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | 第ｘｉｉ因子インヒビターおよびｃ１−インヒビターを使用する組合せ療法 |
| CA2966332C (en) * | 2014-11-03 | 2024-04-16 | Thrombolytic Science, Llc | Methods and compositions for safe and effective thrombolysis |
| WO2016164358A1 (en) | 2015-04-06 | 2016-10-13 | True North Therapeutics, Inc. | Humanized anti-c1s antibodies and methods of use thereof |
| EP3302529A4 (en) | 2015-06-03 | 2019-02-06 | The Children's Hospital Medical Center | COMPOSITIONS AND METHODS FOR TREATING GALLENA GANGATRESIA IN NEWBORNS |
| CA3005906A1 (en) * | 2015-11-19 | 2017-05-26 | Shire Human Genetic Therapies, Inc. | Recombinant human c1 esterase inhibitor and uses thereof |
| US20190175683A1 (en) | 2016-08-05 | 2019-06-13 | Csl Behring Gmbh | Pharmaceutical formulations of c1 esterase inhibitor |
| WO2018037046A1 (en) | 2016-08-23 | 2018-03-01 | Csl Behring Gmbh | Method of preventing acute attacks of hereditary angioedema associated with c1 esterase inhibitor deficiency |
| WO2018232305A1 (en) | 2017-06-16 | 2018-12-20 | Thrombolytic Science, Llc | Methods and compositions for thrombolysis |
| EP3681517B1 (en) | 2017-09-15 | 2024-05-08 | Cedars-Sinai Medical Center | C1 esterase inhibitors for use in improving organ function in organ transplant patients |
| WO2019166572A1 (en) | 2018-02-28 | 2019-09-06 | Pharming Intellectual Property B.V. | Pharmaceutical system for transdermal administration of a c1 -esterase inhibitor |
| BR112020017626A2 (pt) | 2018-02-28 | 2020-12-22 | Pharming Intellectual Property B.V. | Tratamento e prevenção de pré-eclâmpsia |
| US20210380636A1 (en) | 2018-10-17 | 2021-12-09 | Csl Behring Gmbh | Process for purifying c1-inh |
| WO2021001525A1 (en) | 2019-07-04 | 2021-01-07 | Csl Behring Gmbh | Process for purifying c1-inh |
| KR102191500B1 (ko) | 2020-03-30 | 2020-12-15 | 국립낙동강생물자원관 | 초석잠 추출물을 포함하는 기억력 및 인지기능 개선, 허혈 재관류 손상 예방 및 개선용 조성물 |
| EP3895726A1 (en) | 2020-04-17 | 2021-10-20 | Pharming Intellectual Property BV | Using c1 esterase inhibitor to treat viral infection-related acute respiratory distress |
| KR102217607B1 (ko) | 2020-06-01 | 2021-02-18 | 국립낙동강생물자원관 | 석창포 추출물을 포함하는 기억력 및 인지기능 개선, 허혈 재관류 손상 예방 및 개선용 조성물 |
| KR102191452B1 (ko) | 2020-06-30 | 2020-12-15 | 주식회사 에이치비헬스케어 | 곶감 추출물을 포함하는 기억력 및 인지기능 개선, 허혈 재관류 손상 예방 및 개선용 조성물 |
| EP4247416A1 (en) | 2020-11-20 | 2023-09-27 | CSL Behring GmbH | Method for treating antibody-mediated rejection |
| EP4366761A1 (en) | 2021-07-09 | 2024-05-15 | Pharming Intellectual Property B.V. | Using c1 esterase inhibitor to treat viral infection-related symptoms |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1402897T3 (da) | 1999-05-14 | 2006-12-27 | Steffen Thiel | Hidtil ukendte indikationer af mannanbindende lectin (MBL) til behandling af immunkompromitterede individer |
| US7067713B2 (en) | 2000-01-31 | 2006-06-27 | Pharming Intellectual Property B.V. | C1 Inhibitor produced in the milk of transgenic non-human mammals |
| EP1252184B1 (en) | 2000-01-31 | 2008-01-02 | Pharming Intellectual Property B.V. | Human c1 inhibitor produced in the milk of transgenic mammals |
| JP2004100982A (ja) * | 2002-09-05 | 2004-04-02 | Denso Corp | 熱交換器 |
| EP1551987A1 (en) | 2002-10-17 | 2005-07-13 | Pharming Intellectual Property B.V. | Protein modification |
| PL1626736T3 (pl) * | 2003-05-16 | 2021-05-04 | Pharming Intellectual Property B.V. | Inhibitor c1 o krótkim okresie półtrwania do leczenia przejściowego |
| US8071532B2 (en) | 2005-12-21 | 2011-12-06 | Pharming Intellectual Property B.V. | Use of C1 inhibitor for the prevention of ischemia-reperfusion injury |
-
2006
- 2006-12-19 US US12/158,987 patent/US8071532B2/en active Active
- 2006-12-19 PL PL06824316T patent/PL1965831T3/pl unknown
- 2006-12-19 WO PCT/NL2006/050321 patent/WO2007073186A2/en active Application Filing
- 2006-12-19 EP EP06824316A patent/EP1965831B1/en active Active
- 2006-12-19 AU AU2006327989A patent/AU2006327989B2/en active Active
- 2006-12-19 EP EP11172880.4A patent/EP2380587B1/en active Active
- 2006-12-19 KR KR1020087017880A patent/KR101508668B1/ko active IP Right Grant
- 2006-12-19 JP JP2008547134A patent/JP5394748B2/ja active Active
- 2006-12-19 SI SI200632219T patent/SI2380587T1/en unknown
- 2006-12-19 DK DK11172880.4T patent/DK2380587T3/en active
- 2006-12-19 PL PL11172880T patent/PL2380587T3/pl unknown
- 2006-12-19 CA CA2632400A patent/CA2632400C/en active Active
- 2006-12-19 AT AT06824316T patent/ATE516043T1/de active
- 2006-12-19 NZ NZ568749A patent/NZ568749A/en unknown
-
2008
- 2008-06-15 IL IL192180A patent/IL192180A/en active IP Right Grant
-
2011
- 2011-08-25 HR HR20110622T patent/HRP20110622T1/hr unknown
- 2011-10-05 CY CY20111100950T patent/CY1112452T1/el unknown
- 2011-10-11 US US13/271,107 patent/US8415288B2/en active Active
-
2013
- 2013-02-04 JP JP2013019186A patent/JP2013126992A/ja active Pending
- 2013-02-25 US US13/776,529 patent/US9211318B2/en active Active
- 2013-10-17 IL IL228954A patent/IL228954A/en active IP Right Grant
-
2017
- 2017-11-13 HR HRP20171738TT patent/HRP20171738T1/hr unknown
-
2018
- 2018-01-10 CY CY20181100029T patent/CY1119818T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20110622T1 (hr) | Upotreba inhibitora c1 u sprječavanju ishemijsko-reperfuzijske ozljede | |
| EP2875825A1 (en) | Composition for preventing or treating rheumatoid arthritis | |
| MXPA01007956A (es) | Polipeptido antimicrobiano/neutralizador de endotoxina. | |
| ZA200800533B (en) | Glycosylated IL-7, preparation and uses | |
| RU2014117291A (ru) | Рекомбинантный человеческий белок naglu и его применение | |
| ATE489462T1 (de) | Antimikrobielles polypeptid und nutzung davon | |
| MX2009008413A (es) | Tratamiento y prevencion de enfermedades neurodegenerativas usando terapia genica. | |
| MXPA02000196A (es) | Proteinas y genes anti-patogenicos de girasol y sus usos. | |
| NZ596043A (en) | Allergy inhibitor compositions and kits and methods of using the same | |
| Zhang et al. | Effects of ischemic preconditioning on blood–brain barrier permeability and MMP-9 expression of ischemic brain | |
| AU2014318247B2 (en) | Novel peptides and analogs for use in the treatment of oral mucositis | |
| WO2021251673A1 (ko) | 치주질환 또는 탈구성 외상 치아의 예방 또는 치료용 약학 조성물 | |
| ZA202300505B (en) | Compositions useful for treatment of charcot-marie-tooth disease | |
| WO2005053610A3 (en) | Diamine and iminodiacetic acid hydroxamic acid derivatives | |
| CA2748392C (en) | Use of interleukin-22 for the prevention and/or treatment of multiple organ dysfunction syndrome (mods) | |
| MX2007002491A (es) | Uso farmaceutico de graptopetalo y plantas relacionadas. | |
| EP3384923A1 (en) | C4bp-based compounds for treating immunological diseases | |
| BRPI0411865A (pt) | redução da descoloração em espumas brancas de poliuretano | |
| PL371254A1 (en) | Synthetic peptides and uses thereof for the prevention and therapy of cancer invasion and metastasis | |
| Kaplan et al. | Genetic Modification of Response to Spleen Shielding in Irradiated Mice. | |
| MX2023001565A (es) | Vectores aav que codifican parkin y usos de los mismos. | |
| CZ285155B6 (cs) | Peptidy s organoprotektivním účinkem, způsob jejich výroby a farmaceutické prostředky s jejich obsahem | |
| WO2005020935A3 (en) | Method and composition of administering radioprotectants | |
| AR127311A1 (es) | VACUNAS DE ÁCIDOS NUCLEICOS PARA EL CORONAVIRUS BASADAS EN SECUENCIAS DERIVADAS DE LA CEPA DELTA DEL SARS-CoV-2 | |
| AR127675A1 (es) | Terapia génica para el tratamiento de la ht1 |